CFBD CI Prof Michael Kassiou, founder of Kinoxis, has secured a lucrative partnership with Boehringer Ingelheim to investigate drugs that treat aggression and social withdrawal in people with psychiatric disorders.

Michael developed small molecules that interact with oxytocin receptors which could be used to target oxytocin receptors with the aim of creating medicine to treat schizophrenia, depression and other neuropsychiatric illness. Read the full article in the Sydney Morning Herald from 4 May.